Revolution Medicines to report Q2 financial results after market close, hosts webcast updatePUBT·5 hours agoRVMD-1.60%
US Biotech Sector Nears Commercialization Inflection Point on Key FDA ApprovalsGlobal Report·16 hours agoCRSP+0.19%GENB-0.46%
I'm Told These Non-Traditional Equities—From Space Tech to AI Infra—Are Gearing Up for Major OverhaulsGlobal Report·1 day ago, 04:13 AMLUNR-7.92%SIDU-5.35%
ABN Amro Investment Solutions Purchases Shares of 6,794 Revolution Medicines, Inc. $RVMDMarket Beat·Jul 26 at 02:04 AMRVMD-1.60%JHG0.00%
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price TargetTip Ranks·Jul 22 at 04:35 PMRVMD-1.60%
Revolution Medicines says FDA accepts daraxonrasib NDA for previously treated metastatic pancreatic cancerPUBT·Jul 22 at 03:11 PMRVMD-1.60%
16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·Jul 21 at 03:28 PMERAS-2.42%RVMD-1.60%
The Unbundling of Sectors: Decoding the Long Tail of the 2026 MarketGlobal Report·Jul 21 at 04:13 AMFLUX-9.29%CCK-1.19%
4 Health Care Stocks Whale Activity In Today’s Sessionbenzinga_article·Jul 17 at 12:35 PMTEM-3.15%RVMD-1.60%
21:44 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·Jul 14 at 08:45 PMERAS-2.42%RVMD-1.60%
ERAS DEADLINE NOTICE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitPR Newswire·Jul 9 at 05:05 AMERAS-2.42%
9 Health Care Stocks Whale Activity In Today’s Sessionbenzinga_article·Jul 8 at 12:35 PMTMO+1.00%DHR-1.29%
